Key Insights

Highlights

Success Rate

78% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

9.5%

2 terminated out of 21 trials

Success Rate

77.8%

-8.7% vs benchmark

Late-Stage Pipeline

10%

2 trials in Phase 3/4

Results Transparency

100%

7 of 7 completed with results

Key Signals

7 with results78% success

Data Visualizations

Phase Distribution

19Total
Not Applicable (3)
Early P 1 (1)
P 1 (8)
P 2 (5)
P 3 (2)

Trial Status

Completed7
Recruiting7
Active Not Recruiting3
Terminated2
Withdrawn2

Trial Success Rate

77.8%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT05235165Phase 3RecruitingPrimary

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

NCT02364557Phase 2Completed

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

NCT01590069Phase 1Active Not RecruitingPrimary

Aerosolized Aldesleukin in Treating Patients With Lung Metastases

NCT02306161Phase 3Active Not Recruiting

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

NCT03965234Phase 1Recruiting

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

NCT06482073Recruiting

Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care (Interception for Suspected Lung Cancer)

NCT03164486Early Phase 1Active Not Recruiting

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

NCT02738606Phase 2Terminated

Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery

NCT03582124Phase 1Recruiting

Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

NCT05039632Phase 1Recruiting

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

NCT03422302Not ApplicableRecruiting

Continuous Positive Airway Pressure Device or Deep Inspiration Breath Hold in Reducing Tumor Motion in Patients Undergoing Stereotactic Body Radiation Therapy for Lung Cancer

NCT05802186Not ApplicableRecruiting

Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study

NCT05717140Phase 1Withdrawn

Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung

NCT04987281Phase 2Withdrawn

Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study

NCT03749460Phase 1Completed

Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers

NCT02693080Phase 1Completed

CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy

NCT02484443Phase 2CompletedPrimary

Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

NCT01014598Phase 1CompletedPrimary

Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis

NCT00862680Completed

4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis

NCT02062632Phase 2Terminated

Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy

Scroll to load more

Research Network

Activity Timeline